Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 203

Sort by

Sort Order Select

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

Journal Articles

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Andrea Piolatto, MS, Carmen Gaglioti, MD, Filomena Longo, MD, Silvia De Francia, PhD, Sarah Allegra, PhD, Paola Berchialla, PhD, Antonio Piga

Blood (2019) 134 (Supplement_1): 3547.

https://doi.org/10.1182/blood-2019-122030

Published: 2019

Journal Articles

Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation

Sarah Kelliher, MBBS, Luisa Weiss, MSc, Paulina Szklanna, PhD, Karl Egan, PhD, Tadhg Prendiville, MB BCh BAO, Eric Moran, MB BCh BAO, Georgi Petrov, MB BCh BAO, Alfonso Blanco, PhD, Aine Lennon, MSc, Sean Murphy, MD, John Keaney, MD, Fionnuala Ni Ainle, PhD, Patricia Maguire, PhD

Blood (2019) 134 (Supplement_1): 2437.

https://doi.org/10.1182/blood-2019-126166

Published: 2019

Journal Articles

The Multidrug Transporter MRP4/ABCC4 Involved in the Leukemia Clinical Course Specifies the Novel PEL Human Blood Group System

Blood (2019) 134 (Supplement_1): 715.

https://doi.org/10.1182/blood-2019-124082

Published: 2019

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Irina N. Shipounova, PhD, Nataliya A. Petinati, MD PhD, Nina J. Drize, PhD, Aminat A. Magomedova, MD PhD, Ekaterina A. Fastova, MD, Sergey K. Kravchenko, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anna G. Turkina, Prof., MD, Elena N. Parovichnikova, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5014.

https://doi.org/10.1182/blood-2019-123396

Published: 2019

Journal Articles

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Mohamed A Yassin, MBBS, MSc, Mohammad Abdul-Jaber Abdulla, MD, Feryal Abbas, MD PhD, Prem Chandra, PhD, Abdulqadir Jeprel Nashwan, BSN, MSN, Rola S Ghasoub, BSC, Nancy Kassem, BSC, Ahmad Al Sabbagh, MD, Zafar Nawaz, PhD, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5912.

https://doi.org/10.1182/blood-2019-125700

Published: 2019

Journal Articles

Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models

Gabriele Greve, PhD, Julia Schüler, DVM, Eva Oswald, PhD, Michael Lübbert

Blood (2019) 134 (Supplement_1): 2644.

https://doi.org/10.1182/blood-2019-126514

Published: 2019

Journal Articles

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 4204.

https://doi.org/10.1182/blood-2019-126538

Published: 2019

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Stephan Stilgenbauer, Danjie Zhang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4297.

https://doi.org/10.1182/blood-2019-130912

Published: 2019

Journal Articles

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Jorge Monge, MD, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Jin Guo, MD, Jorge Contreras, MD, Kathleen Pogonowski, RN, Natalie Agudo, RN, Danielle Guarneri, BS, CCRP, Brielle Liotta, BS, Eloisi Caldas Lopes, PhD, Roger Pearse, MD PhD, Morton Coleman, MD, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2019) 134 (Supplement_1): 5563.

https://doi.org/10.1182/blood-2019-127697

Published: 2019

Journal Articles

Long Term Remission Achieved By Fostamatinib in ITP: A Case Report

Waleed Ghanima, MD PhD, Tjønnfjord Eirik, MD PhD

Blood (2019) 134 (Supplement_1): 4901.

https://doi.org/10.1182/blood-2019-128359

Published: 2019

Journal Articles

Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance

Ami B. Patel, MD, Anthony D. Pomicter, MS, Dongqing Yan, Anna M. Eiring, PhD, Anca Franzini, PhD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2018-99-117276

Published: 2018

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis

Ifeyinwa Osunkwo, MD MPH, Shelby Merchant, PharmD, Rachel Crawford, PharmD, BCPS, Katherine Rector, PharmD, BCPS, Justin Arnall, PharmD, CPP, BCOP, James T Symanowski, PhD, Padmaja Veeramreddy, MD

Blood (2018) 132 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2018-99-116848

Published: 2018

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas

Yunxin Chen, MBBS, Chandramouli Nagarajan, Nicholas Francis Grigoropoulos, Shin-Yeu Ong, MD, Kit Yan Loh, Allan Zhi Kai Goh, Yeow Tee Goh, MBBS, MD, Yuh Shan Lee, FRCPath, MRCP, MBBS

Blood (2018) 132 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2018-99-112732

Published: 2018

Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD

Blood (2018) 132 (Supplement 1): 5233.

https://doi.org/10.1182/blood-2018-99-117485

Published: 2018

Journal Articles

The Effect of TET Mutations on DNA Methyltransferase Cytotoxicity and ERV Induction in B and T Cell Malignancies

Juan Carlos Nogues, BS, Zi Michael Wang, BS, Sarah School Chisholm, MA, Mitcell Smith, MD PhD, Eduardo Sotomayor, MD, Katherine Chiappinelli, PhD

Blood (2018) 132 (Supplement 1): 5157.

https://doi.org/10.1182/blood-2018-99-120281

Published: 2018

Journal Articles

In Elderly Patients with Newly Diagnosed Aggressive B-Cell Lymphoma, the Rate of Change in Body Weight after the First Course R-CHOP (-like) Chemo Therapy Has Effect on Their Survival

Muramatsu Ayako, MD, Nagata Hiroaki, MD, Kuriyama Kodai, MD PhD, Hirakawa Yoshiko, MD PhD, Oshiro Muneo, MD PhD, Iwai Toshiki, MD PhD, Uchiyama Hitoji, MD PhD

Blood (2018) 132 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2018-99-117207

Published: 2018

NARROW

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Rivaroxaban Reduces the Levels of Extracellular Vesicles in Patients with Venous Thromboembolism and Non-Valvular Atrial Fibrillation

The Multidrug Transporter MRP4/ABCC4 Involved in the Leukemia Clinical Course Specifies the Novel PEL Human Blood Group System

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Long Term Remission Achieved By Fostamatinib in ITP: A Case Report

Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

The Effect of TET Mutations on DNA Methyltransferase Cytotoxicity and ERV Induction in B and T Cell Malignancies

In Elderly Patients with Newly Diagnosed Aggressive B-Cell Lymphoma, the Rate of Change in Body Weight after the First Course R-CHOP (-like) Chemo Therapy Has Effect on Their Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only